Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
ANI Pharmaceuticals To Present At The Guggenheim Biotech Conference
The live and archived webcast will be accessible from the Company's website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days.
AI Tool to Slash Pharma Development Costs by Predicting Drug Trial Outcomes
A Lloyd's of London company partnered with GATC Health to fund and insure prospective drug trials that pass the test of a new AI technology.
Pharmaceutical Technology4d
Pharmaceutical Technology Excellence Awards 2024 – Winners Announced!
The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...
JD Supra1d
Biotech Licensing Caselaw Update - 2024 Year in (Brief) Review
Last year was a surprisingly big one for legal decisions impacting the biotechnology transactions and licensing space. Given ...